Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways

Area of Science:

• Bone biology
• Cell signaling
• Osteocyte function

Background:

• Sclerostin is an osteocyte-expressed protein with known bone catabolic effects.
• Its antagonism of bone morphogenetic protein (BMP) and Wnt signaling pathways is established, but mechanisms remain unclear.
• Previous studies showed sclerostin antagonizes Wnt signaling but its effect on BMP signaling is context-dependent.

Purpose of the Study:

• To elucidate the precise molecular mechanisms by which sclerostin antagonizes BMP and Wnt signaling.
• To investigate the role of sclerostin in regulating BMP7 secretion and signaling within osteocytes.
• To analyze the in vivo effects of sclerostin on Wnt and BMP signaling in different bone compartments.

Main Methods:

• In vitro cell culture experiments exposing cells to exogenous Wnt3a and BMP7 ligands and sclerostin.
• Analysis of protein-protein interactions between sclerostin and BMP7 domains.
• Assessment of intracellular BMP7 retention and degradation.
• In vivo studies using sclerostin knock-out mice to evaluate Wnt and BMP signaling in osteoblasts and osteocytes.

Main Results:

• Sclerostin inhibits BMP7 secretion when co-expressed in the same cell, unlike when added exogenously.
• Sclerostin directly interacts with BMP7 (mature and pro-domain), causing intracellular retention and proteasomal degradation.
• Sclerostin antagonizes Wnt signaling in osteoblasts and osteocytes and BMP7 signaling primarily in osteocytes co-expressing both proteins.

Conclusions:

• Sclerostin exerts bone catabolic effects through paracrine/autocrine Wnt antagonism.
• Sclerostin selectively inhibits BMP7 signaling in osteocytes by blocking BMP7 secretion and promoting its degradation.
• These findings reveal novel intracellular mechanisms for sclerostin's regulation of BMP signaling, impacting bone metabolism.